The antitumour activity of crizotinib was also confirmed in a phase II prospective multicentre two-arm trial in patients with NSCLC with ROS1 rearrangements (cohort A; n = 26) or MET deregulation (cohort B; n = 26) [104]. This evidence concerns the gene MET and non-small cell lung carcinoma.